Scan to Download ios&Android APP

Trade Landos Biopharma, Inc. - LABP CFD

0.87
5.43%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 0.92
Open* 0.86
Day's Range* 0.86 - 0.86
1-Year Change* -1.15%
Volume N/A
Average Vol. (3m) 2.16093
52 wk Range N/A
Market Cap 40.2549
P/E Ratio N/A
Shares Outstanding 40254900
Revenue N/A
EPS -1.46431
Dividend (Yield %) N/A
Beta N/A
Next Earnings Date Nov 14, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 16, 2022 0.92 -0.06 -6.12% 0.98 1.02 0.91
Aug 15, 2022 0.98 -0.05 -4.85% 1.03 1.03 0.89
Aug 12, 2022 1.03 0.00 0.00% 1.03 1.04 0.98
Aug 11, 2022 1.06 -0.13 -10.92% 1.19 1.20 1.05
Aug 10, 2022 1.20 0.12 11.11% 1.08 1.21 1.08
Aug 9, 2022 1.10 -0.17 -13.39% 1.27 1.34 1.07
Aug 8, 2022 1.24 0.01 0.81% 1.23 1.26 1.20
Aug 5, 2022 1.20 0.08 7.14% 1.12 1.21 1.07
Aug 4, 2022 1.11 0.20 21.98% 0.91 1.15 0.88
Aug 3, 2022 0.89 -0.02 -2.20% 0.91 0.94 0.79
Aug 2, 2022 0.78 0.04 5.41% 0.74 0.78 0.73
Aug 1, 2022 0.75 -0.02 -2.60% 0.77 0.77 0.74
Jul 29, 2022 0.75 -0.02 -2.60% 0.77 0.81 0.74
Jul 28, 2022 0.80 -0.01 -1.23% 0.81 0.82 0.78
Jul 27, 2022 0.81 -0.04 -4.71% 0.85 0.85 0.76
Jul 26, 2022 0.79 0.04 5.33% 0.75 0.80 0.74
Jul 25, 2022 0.81 0.03 3.85% 0.78 0.82 0.73
Jul 22, 2022 0.83 -0.01 -1.19% 0.84 0.85 0.83
Jul 21, 2022 0.80 -0.04 -4.76% 0.84 0.84 0.78
Jul 20, 2022 0.82 0.05 6.49% 0.77 0.82 0.74

Landos Biopharma, Inc. Events

Time (UTC) Country Event
Monday, November 14, 2022
13:30
  US
Q3 2022 Landos Biopharma Inc Earnings Release
View all events
  • Annual
  • Quarterly
2018 2019 2020 2021
Total revenue 0 0 0 18
Total Operating Expense 7.939 13.29 30.676 56.816
Selling/General/Admin. Expenses, Total 1.136 1.478 5.338 15.252
Research & Development 6.803 11.812 25.338 41.564
Operating Income -7.939 -13.29 -30.676 -38.816
Interest Income (Expense), Net Non-Operating -0.11 -0.337 0.077 -0.018
Other, Net 2.005 0.16 0.455 0.412
Net Income Before Taxes -6.044 -13.467 -30.144 -38.422
Net Income After Taxes -6.044 -13.467 -30.144 -38.422
Net Income Before Extra. Items -6.044 -13.467 -30.144 -38.422
Net Income -6.044 -13.467 -30.144 -38.422
Income Available to Common Excl. Extra. Items -6.044 -13.467 -30.144 -38.422
Income Available to Common Incl. Extra. Items -6.044 -13.467 -30.144 -38.422
Diluted Net Income -6.044 -13.467 -30.144 -38.422
Diluted Weighted Average Shares 39.1632 39.1632 40.1176 37.5585
Diluted EPS Excluding Extraordinary Items -0.15433 -0.34387 -0.75139 -1.02299
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.15433 -0.34387 -0.75139 -1.02299
Revenue 18
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 0 18 0 0 0
Total Operating Expense 9.9 14.118 12.403 20.396 14.953
Selling/General/Admin. Expenses, Total 2.646 2.596 3.059 6.952 3.853
Research & Development 7.254 11.522 9.344 13.444 10.8
Operating Income -9.9 3.882 -12.403 -20.396 -14.953
Interest Income (Expense), Net Non-Operating 0.018 -0.005 -0.01 -0.021 0.001
Other, Net 0.064 0.22 -0.191 0.32 0.088
Net Income Before Taxes -9.818 4.097 -12.604 -20.097 -14.864
Net Income After Taxes -9.818 4.097 -12.604 -20.097 -14.864
Net Income Before Extra. Items -9.818 4.097 -12.604 -20.097 -14.864
Net Income -9.818 4.097 -12.604 -20.097 -14.864
Income Available to Common Excl. Extra. Items -9.818 4.097 -12.604 -20.097 -14.864
Income Available to Common Incl. Extra. Items -9.818 4.097 -12.604 -20.097 -14.864
Diluted Net Income -9.818 4.097 -12.604 -20.097 -14.864
Diluted Weighted Average Shares 26.0705 34.3848 39.9621 40.246 40.2549
Diluted EPS Excluding Extraordinary Items -0.37659 0.11915 -0.3154 -0.49935 -0.36925
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.37659 0.11915 -0.3154 -0.49935 -0.36179
Revenue 18 0 0
Unusual Expense (Income) 0.3
  • Annual
  • Quarterly
2018 2019 2020 2021
Total Current Assets 2.492 50.11 29.888 92.146
Cash and Short Term Investments 0.359 49.965 28.134 90.88
Cash & Equivalents 0.359 9.808 2.416 8.305
Short Term Investments 0 40.157 25.718 82.575
Total Receivables, Net 2.092 0.001 0.154
Prepaid Expenses 0.041 0.144 0.202 1.266
Total Assets 2.796 50.48 30.332 92.879
Property/Plant/Equipment, Total - Net 0.304 0.359 0.444 0.707
Property/Plant/Equipment, Total - Gross 0.413 0.571 0.793 1.248
Accumulated Depreciation, Total -0.109 -0.212 -0.349 -0.541
Other Long Term Assets, Total 0 0.011 0 0.026
Total Current Liabilities 1.796 3.026 11.034 16.611
Accounts Payable 1.692 2.048 8.606 12.908
Accrued Expenses 0.104 0.978 1.939 3.703
Notes Payable/Short Term Debt 0 0 0 0
Total Liabilities 1.796 3.026 11.31 16.611
Total Long Term Debt 0 0 0 0
Total Equity 1 47.454 19.022 76.268
Redeemable Preferred Stock 0.032 73.037 73.037 0
Common Stock 0.059 0.063 0.071 0.403
Additional Paid-In Capital 10.044 0.016 1.633 170.241
Retained Earnings (Accumulated Deficit) -9.135 -25.585 -55.729 -94.151
Other Equity, Total 0 -0.077 0.01 -0.225
Total Liabilities & Shareholders’ Equity 2.796 50.48 30.332 92.879
Total Common Shares Outstanding 39.1632 39.1632 40.1176 40.2549
Other Current Assets, Total 1.398 0
Other Current Liabilities, Total 0.489 0
Other Liabilities, Total 0.276 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 109.745 117.727 104.318 92.146 77.359
Cash and Short Term Investments 106.358 115.127 102.67 90.88 73.796
Cash & Equivalents 8.572 18.687 17.893 8.305 11.288
Short Term Investments 97.786 96.44 84.777 82.575 62.508
Total Receivables, Net 0.001 0.002 0.003
Prepaid Expenses 3.386 2.598 1.645 1.266 3.563
Other Current Assets, Total 0 0 0 0
Total Assets 110.21 118.291 105.098 92.879 77.61
Property/Plant/Equipment, Total - Net 0.465 0.564 0.78 0.707 0.251
Total Current Liabilities 8.819 12.53 11.095 16.611 15.507
Accounts Payable 8.2 10.685 10.114 12.908 9.803
Accrued Expenses 0.364 1.59 0.726 3.703 5.704
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.255 0.255 0.255 0
Total Liabilities 9.031 12.679 11.18 16.611 15.507
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.212 0.149 0.085 0
Total Equity 101.179 105.612 93.918 76.268 62.103
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.399 0.399 0.401 0.403 0.403
Additional Paid-In Capital 166.429 166.805 167.44 170.241 171.182
Retained Earnings (Accumulated Deficit) -65.547 -61.45 -74.054 -94.151 -109.015
Other Equity, Total -0.102 -0.142 0.131 -0.225 -0.467
Total Liabilities & Shareholders’ Equity 110.21 118.291 105.098 92.879 77.61
Total Common Shares Outstanding 40.1176 40.1176 40.2356 40.2549 40.2549
Other Long Term Assets, Total 0.026
Property/Plant/Equipment, Total - Gross 1.125
Accumulated Depreciation, Total -0.874
  • Annual
  • Quarterly
2018 2019 2020 2021
Net income/Starting Line -6.044 -13.467 -30.144 -38.422
Cash From Operating Activities -6.896 -9.874 -22.962 -27.061
Cash From Operating Activities 0.08 0.103 0.137 0.196
Non-Cash Items 0.369 0.213 1.174 5.274
Cash Interest Paid 0.004 0.027 0
Changes in Working Capital -1.301 3.277 5.871 5.891
Cash From Investing Activities -0.043 -40.325 14.131 -58.706
Capital Expenditures -0.043 -0.158 -0.181 -0.44
Other Investing Cash Flow Items, Total 0 -40.167 14.312 -58.266
Cash From Financing Activities 5 59.648 1.518 91.607
Issuance (Retirement) of Stock, Net 5 51.668 1.518 93.514
Issuance (Retirement) of Debt, Net 0 7.98 0
Net Change in Cash -1.939 9.449 -7.392 5.889
Foreign Exchange Effects -0.079 0.049
Financing Cash Flow Items -1.907
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -9.818 -5.721 -18.325 -38.422 -14.864
Cash From Operating Activities -12.56 -3.16 -15.004 -27.061 -16.502
Cash From Operating Activities 0.043 0.093 0.141 0.196 0.353
Non-Cash Items 1.271 2.01 3.087 5.274 1.381
Changes in Working Capital -4.056 0.458 0.093 5.891 -3.372
Cash From Investing Activities -72.048 -71.333 -60.502 -58.706 19.506
Capital Expenditures -0.064 -0.213 -0.477 -0.44 -0.007
Other Investing Cash Flow Items, Total -71.984 -71.12 -60.025 -58.266 19.513
Cash From Financing Activities 90.764 90.764 90.983 91.607 0
Issuance (Retirement) of Stock, Net 90.764 90.764 90.983 93.514 0
Net Change in Cash 6.156 16.271 15.477 5.889 2.983
Foreign Exchange Effects 0 0 0.049 -0.021
Financing Cash Flow Items -1.907

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Landos Biopharma, Inc. Company profile

About Landos Biopharma Inc

Landos Biopharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The Company through its artificial intelligence (AI)-based precision medicine platform, LANCE platform, identifies therapeutic targets based on predictions of immunometabolic function and create therapeutic candidates to engage those targets in areas of unmet medical need. Its platform discovers small molecule therapeutics for patients with autoimmune diseases that targets mechanisms of action, including LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. It identifies novel immunometabolic targets and product candidates across indications, such as ulcerative colitis (UC), Crohn’s disease (CD), eosinophilic esophagitis (EoE), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its Omilancor is an oral, gut restricted LANCL2 agonist in development for the treatment of UC, CD and EoE.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Landos Biopharma Inc revenues increased from $0K to $18M. Net loss decreased 3% to $18.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.48 to -$0.57.

Industry: Biotechnology & Medical Research (NEC)

1800 Kraft Drive, Suite 216
BLACKSBURG
VIRGINIA 24060
US

Income statement

People Also Watch

US Crude Oil Spot

87.15 Price
+0.500% 1D Chg, %
Long position overnight fee 0.0059%
Short position overnight fee -0.0209%
Overnight fee time 21:00 (UTC)
Spread 0.03

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading